STOCKHOLM, June 18, 2024 /PRNewswire/ -- Oblique
Therapeutics, a leading biotechnology company specialising in the
development of new drug candidates, is pleased to announce today
that they have entered into an agreement with the KTH Royal
Institute of Technology to utilise KTH's state-of-the-art
supercomputer resources for analysing protein structures. This
partnership aims to accelerate research and development in the area
of innovative treatments for various illnesses.
The PDC Center for High Performance Computing (PDC) at KTH hosts
the most powerful supercomputer within the National Academic
Infrastructure for Supercomputing in Sweden (NAISS). Part of that system is
available for industrial use. This resource will give Oblique
Therapeutics an unsurpassed capacity to process and analyse large
quantities of data, which is vital for understanding the
development of protein structures and their biochemical properties.
By combining Oblique Therapeutics' expertise in drug development
research with KTH's advanced technological resources, it is
expected that this collaboration will lead to significant progress
in biomedical R&D. The collaboration will focus on accelerating
the development of therapeutic antibodies for some of the most
important target proteins related to neurological illnesses,
including chronic pain, migraine and more.
About Oblique Therapeutics
Oblique Therapeutics is a biotechnology company that focuses on
developing new therapeutic methods for treating severe illnesses,
especially in the area of pain management and also for other
conditions. The company uses pioneering technology and innovative
research methods to discover and develop new drug candidates.
About the KTH Royal Institute of Technology (KTH)
KTH is the biggest technical university in Sweden and is one of Europe's leading technical institutions. The
university is known for its research and education in technology
and science, and its advanced research infrastructure, including
the supercomputer, supports a broad range of scientific
disciplines. The supercomputer in question is one of the most green
computers in the world thanks to its energy-efficient architecture
and due to using renewable electricity and recycling heat.
"We are delighted to collaborate with KTH and benefit from
their advanced computational resources and to combine those with
our innovative approach in order to accelerate our research and
development achievements," says the leading researcher in the
project, Dr. Anna Reymer, from
Oblique Therapeutics. "This collaboration will further
strengthen our position within the biotechnology branch and
increase our chances of delivering ground-breaking therapies to
patients all over the world."
"On behalf of KTH, PDC is proud to contribute to the Swedish
high-tech industry. The collaboration with Oblique Therapeutics is
an outstanding example of this and falls within the scope of
biotechnology, which is an area where KTH researchers are highly
active and very successful," says Patrick Norman, PDC's director.
For additional information, pls contact: Anna Reymer (Anna.Reymer@obliquet.com),
Olof Larsson
(olof.larsson@obliquet.com) & Michaela Barth
(caela@kth.se).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/oblique-therapeutics-ab/r/oblique-therapeutics-and-the-kth-royal-institute-of-technology--kth--have-entered-into-a-strategic-c,c4003211
The following files are available for download:
https://mb.cision.com/Public/16877/4003211/9390f7ac0070f265.pdf
|
PR Oblique Therapeutics
Cision
|
View original
content:https://www.prnewswire.co.uk/news-releases/oblique-therapeutics-and-the-kth-royal-institute-of-technology-kth-have-entered-into-a-strategic-collaboration-to-analyse-protein-structures-using-supercomputers-302175679.html